Tests acalabrutinib with rituximab in older or frail people with lymphoma
Tests acalabrutinib plus rituximab in older or frail adults newly diagnosed with lymphoma.
Key facts
- Who runs it
- AstraZeneca
- Where
- Beltsville, Berkeley, Des Moines, Detroit, Jacksonville, La Jolla, Lexington, Lubbock, Olympia, Orange, Sioux Falls, Stamford, Tacoma, and Towson, United StatesSee the 14 sitesAlso in 4 other countries, 29 sites
- Trial code
- Registry title
- Study of Acalabrutinib and Rituximab in Untreated Elderly and/or Frail Patients With DLBCL
- Status
- Recruiting
- Phase
- Phase 2
- People taking part
- 80 people, planned
- Started
- 16 Jul 2024
- Expected to end
- 22 Apr 2029
- Type of study
- Interventional
- Treatments tested
- Acalabrutinib
- Rituximab
- Record updated
- 30 October 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for older adults, or frail adults, with diffuse large B-cell lymphoma (DLBCL) who have not been treated yet and cannot have standard chemoimmunotherapy.
- Age
- 80 years or older, or 65 to 79 years and not able to have chemoimmunotherapy. The record lists a maximum age of 99 years.
- Sex
- All sexes can join.
- Disease stage
- DLBCL confirmed by tissue testing, stage II, III or IV (Ann Arbor). At least 1 lesion measuring 10 mm or more on CT or MRI. Performance status of 0, 1 or 2.
- Earlier treatment
- No earlier treatment for DLBCL.
Main reasons for not taking part
- Active hepatitis B or C infection, or HIV infection
- Active lymphoma in the brain or spinal cord area
- History of stroke or bleeding in the skull within 6 months, or a bleeding disorder
- Taking warfarin or similar blood thinners (vitamin K antagonists)
- Major surgery within 30 days, or a live virus vaccine within 28 days
The registry criteria, word for word
Show all 21 criteriaShow less
Who can take part
- ≥ 80 years of age at the time of screening, or
- ≥ 65 to 79 years of age at the time of screening and considered ineligible for chemoimmunotherapy
- Histologically documented DLBCL
- No prior treatment for DLBCL
- Stage II, III, or IV disease by the Ann Arbor Classification
- Eastern Cooperative Oncology Group performance status of 0, 1, or 2 with no deterioration over the previous 2 weeks prior to baseline or day of the first dosing except when due to underlying lymphoma
- At least 1 lesion that can be accurately measured at baseline as ≥ 10 mm in the longest diameter with computed tomography or magnetic resonance imaging and is suitable for accurate repeated measurements
- Adequate organ and marrow function independent of growth factor or transfusion support within 1 week of Screening
Who cannot take part
- History of prior or current malignancy, that would affect compliance with the protocol or interpretation of the results
- History of stroke or intracranial haemorrhage within 6 months before the first dose of study drug
- Major surgical procedure within 30 days of first dose of study intervention or anticipated major surgery during the study timeframe
- Requires or receiving anticoagulation with warfarin or equivalent vitamin K antagonists
- Received a live virus vaccination within 28 days of the first dose of study drug
- Any evidence of diseases (such as severe or uncontrolled systemic diseases, including uncontrolled hypertension, renal transplant, and active bleeding diseases), that would make the study undesirable for the patient or that would impact compliance with the protocol
- Serologic status reflecting active hepatitis B or C infection
- Serological positivity or known infection with HIV
- Active central nervous system involvement by lymphoma, leptomeningeal disease, or spinal cord compression
- Any comorbidity or organ system impairment rated with a single Cumulative Illness Rating Scale-Geriatric score (CIRS-G) of 4 or a total CIRS-G score of > 17
- History of or ongoing confirmed Progressive Multifocal Leukoencephalopathy
- Known active significant infection
- History of bleeding diathesis (eg, haemophilia, von Willebrand disease)
Check if you might fit
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 65 and 99 years old?
Where in United States
Also in 4 other countries, 29 sites
- Beltsville, MarylandHospital not named in the registryTaking people
- Berkeley, CaliforniaHospital not named in the registryNo longer taking part
- Des Moines, IowaHospital not named in the registryTaking people
- Detroit, MichiganHospital not named in the registryTaking people
- Jacksonville, FloridaHospital not named in the registryTaking people
- La Jolla, CaliforniaHospital not named in the registryNo longer taking part
- Lexington, KentuckyHospital not named in the registryNo longer taking part
- Lubbock, TexasHospital not named in the registryTaking people
- Olympia, WashingtonHospital not named in the registryTaking people
- Orange, CaliforniaHospital not named in the registryNo longer taking part
- Sioux Falls, South DakotaHospital not named in the registryNo longer taking part
- Stamford, ConnecticutHospital not named in the registryNo longer taking part
- Tacoma, WashingtonHospital not named in the registryTaking people
- Towson, MarylandHospital not named in the registryTaking people
About the trial
What the trial wants to find out
The study will measure the safety, tolerability, and efficacy with acalabrutinib in combination with rituximab in treatment-naïve elderly and/or frail patients with diffuse large B-cell lymphoma (DLBCL), who are otherwise unsuitable for standard front line chemoimmunotherapy treatments.
The group in the trial
- Acalabrutinib and RituximabTreatment being tested
Patients will receive Dose A of acalabrutinib orally in X dosing schedule beginning on Cycle 1 Day 1 for a maximum of 28 cycles or until 2014 Lugano Classification for Non-Hodgkin's Lymphoma (NHL)-defined disease progression or another discontinuation criterion is met. Patients will also receive an intravenous (IV) infusion of Dose B rituximab on Cycle 1 Day 15 and Dose C of rituximab as an subcutaneous (SC) injection on Day 1 of Cycle 2 through Cycle 8.
Treatment: Acalabrutinib and Rituximab
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorSaves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- A Prospective, Open-Label, Single-Arm, Phase II Study of Acalabrutinib and Rituximab in Untreated Elderly and/or Frail Patients With Diffuse Large B-Cell Lymphoma (ACRUE)
- Plain-language title
- Tests acalabrutinib with rituximab in older or frail people with lymphomaGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Fit questions
- Built from NCT05952024, who can take part
- Record updated
- 30 October 2026